RxDoctor Payments Data

Nichole Hruban

Optometrist · Orange Park, FLNPI 1386805190

Payments from drug & device makers

$5,511in general payments, 2019–2025

Across 90 payments — averaging $61.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Eyevance Pharmaceuticals LLC$601
  • Tarsus Pharmaceuticals, Inc.$544
  • Kala Pharmaceuticals, Inc.$482
  • Bausch & Lomb Americas Inc.$428
  • Amgen$341
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$1813%
  • Food & beverage$5,33097%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,511 in reported general payments places this provider in the 90th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$176,952
Medicare patients
768
Services billed
2,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$30,399
LumiganBimatoprost36$16,985
MieboPerfluorohexyloctane/Pf18$13,616
Latanoprost290$3,014
Brimonidine Tartrate13$1,535
Tobramycin-DexamethasoneTobramycin/Dexamethasone58$1,510
Prednisolone Acetate12$394
Timolol Maleate58$388
MoxifloxacinMoxifloxacin Hcl23$307
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$182
ErythromycinErythromycin Base17$173
Cephalexin24$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,178$47,38475 claims
Bausch & Lomb Americas Inc.Miebo$428$13,61618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →